KR20050024831A - Cosmetics containing natural herb extract having anti-inflammatory effect - Google Patents

Cosmetics containing natural herb extract having anti-inflammatory effect Download PDF

Info

Publication number
KR20050024831A
KR20050024831A KR1020030061716A KR20030061716A KR20050024831A KR 20050024831 A KR20050024831 A KR 20050024831A KR 1020030061716 A KR1020030061716 A KR 1020030061716A KR 20030061716 A KR20030061716 A KR 20030061716A KR 20050024831 A KR20050024831 A KR 20050024831A
Authority
KR
South Korea
Prior art keywords
inflammatory effect
extract
cosmetic composition
inflammatory
jujube
Prior art date
Application number
KR1020030061716A
Other languages
Korean (ko)
Inventor
김동주
김정아
Original Assignee
주식회사 엘지생활건강
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 엘지생활건강 filed Critical 주식회사 엘지생활건강
Priority to KR1020030061716A priority Critical patent/KR20050024831A/en
Publication of KR20050024831A publication Critical patent/KR20050024831A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59Mixtures
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74Biological properties of particular ingredients
    • A61K2800/75Anti-irritant

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

PURPOSE: A cosmetic composition having anti-inflammatory effect comprising herb medicine extracts is provided, which composition inhibits PGE2 formation that is an inflammation inducing eicosanoid in COX-2 pathway without cytotoxicity and allergy inducement. CONSTITUTION: The cosmetic composition having anti-inflammatory effect comprises 0.001 to 30.0 wt.% of the herb medicine extracts including Trichosantes Kirilowii Maxim., jujube and Phellodendron amurense RUPR., wherein the herb medicine extracts are prepared by mixing Trichosantes Kirilowii Maxim., jujube and Phellodendron amurense RUPR. in a weight ratio of 1:2:4, and extracting the mixture with 1,3-butyleneglycol, purified water, alcohol, ethylacetate, acetone or a mixture thereof.

Description

생약추출물을 함유하는 항염효과를 갖는 화장료 조성물{COSMETICS CONTAINING NATURAL HERB EXTRACT HAVING ANTI-INFLAMMATORY EFFECT}Cosmetic composition having anti-inflammatory effect containing herbal extracts {COSMETICS CONTAINING NATURAL HERB EXTRACT HAVING ANTI-INFLAMMATORY EFFECT}

본 발명은 항염효과를 갖는 화장료 조성물에 관한 것으로, 더욱 상세하게는 과루근, 대추 및 황백의 생약 추출물을 유효성분으로 함유하여 항염, 항자극 효과가 우수한 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition having an anti-inflammatory effect, and more particularly to a cosmetic composition having an excellent anti-inflammatory and anti-irritant effect by containing herbal extracts of fruit root, jujube and yellow white as active ingredients.

화장품은 피부를 보호하고 피부의 미화 및 청결을 위해 사용되는 제품이지만, 그 조성으로는 피부 보호 목적과는 상이한 성분들이 제품 형성을 위해 불가피하게 포함된다. 이러한 성분들의 예를 들면 계면활성제, 방부제, 향료, 자외선 차단제, 색소 뿐 아니라, 그밖의 효능, 효과를 부여하기 위한 여러 가지 성분들이 여기에 포함되는데, 이들 성분은 일반적으로 피부에 염증이나, 뾰루지, 부종 등 각종 부작용을 발생시키는 것으로 알려져 있다(Maibach ,H. I., Contact Dermatitis, 6, 369-404, 1980). 또한, 체내로부터 배출되는 피지 및 땀, 화장품 성분 중의 지방산, 고급 알콜, 단백질 성분 등이 피부상에 존재하는 피부 상재균에 의해 독성이 강한 물질로 분해되어 이들에 의해 피부 염증이 유발될 수도 있으며, 태양으로부터 나오는 자외선에 의해서도 피부 염증이 유발된다는 것은 잘 알려진 사실이다.Cosmetics are products used to protect the skin and to beautify and cleanse the skin, but the composition inevitably includes components that are different from the purpose of protecting the skin. Examples of such ingredients include surfactants, preservatives, fragrances, sunscreens, pigments, as well as other ingredients for imparting other benefits and effects, which generally include skin irritation, rashes, It is known to cause various side effects such as edema (Maibach, HI, Contact Dermatitis, 6, 369-404, 1980). In addition, sebum and sweat released from the body, fatty acids in the cosmetic ingredients, higher alcohols, protein components, etc. may be decomposed into a highly toxic substance by the skin flora bacteria present on the skin may cause skin inflammation by these, It is well known that skin irritation is caused by ultraviolet rays from the sun.

염증 반응은 붉어짐(feeling of redness), 따끔거림(prickling feeling), 화끈거림(burning, hotness), 팽윤(swelling), 조직의 변화와 같은 5 가지 현상으로 나타나는데, 이는 해로운 주위 환경, 즉 세균과 같은 외부 이물질의 침입과 기계적 손상으로부터 생체를 보호하려는 생리적인 반응이다. 이러한 염증 현상은 여러 종류의 다형핵 백혈구(PMNs)와 면역 물질의 많은 증가를 초래하며, 이처럼 증가된 세포들은 염증성 세포 산물인 다양한 종류의 단백질 분해효소와 사이토카인 (Cytokine) 등을 분비함으로써 치료 및 방어를 할 수 있게 해준다. 그러나, 이러한 작용은 인접해 있는 조직 세포와 비세포 성분들에 해로운 손상을 일으키기도 한다. 따라서, 적절한 조건 하에서는 염증 초기 상태가 지난 후 정상 기능을 되찾게 되지만, 염증을 자극하는 자극제가 없어지지 않거나 계속해서 만들어질 경우에는 결과적으로 만성 염증이 일어나게 되어 더욱 더 심각한 조직의 손상을 가져온다.Inflammatory reactions occur in five phenomena: feeling of redness, prickling feeling, burning, hotness, swelling, and tissue changes, such as harmful surroundings, such as bacteria. It is a physiological reaction to protect the living body from invasion and mechanical damage of foreign objects. These inflammatory phenomena result in a large increase in various polymorphonuclear leukocytes (PMNs) and immune substances, and these increased cells are treated by secreting various kinds of proteolytic enzymes and cytokines, which are inflammatory cell products. It allows you to defend. However, this action can also cause detrimental damage to adjacent tissue cells and noncellular components. Thus, under proper conditions, normal function is restored after the initial stage of inflammation, but if the irritating stimulant is not lost or continues to be produced, chronic inflammation will result, resulting in even more serious tissue damage.

염증 생성 과정의 핵심 물질은 자극에 의해 활성화된 포스포리파아제 A2 (phospholipase A2, PLA2)라는 효소에 의해 세포막 지질로부터 전환된 아라키돈산 (arachidonic acid)으로, 아라키돈산은 다시 싸이클로옥시게나아제 (cyclooxygenase, 이하 "COX"로 약칭) 또는 리폭시게나아제(lipooxygenase)의 2 가지 경로를 거쳐 염증 매개체인 프로스타글란딘류(prostaglandins), 류코트리엔류 (leukotrienes)로 대사되어 다양한 염증 반응을 매개한다(Thomas. R., Rev. Physiol. Biochem. Pharmacol., 100, 1984).A key substance in the inflammation-producing process is arachidonic acid, which is converted from cell membrane lipids by an enzyme called phospholipase A2 (PLA2) activated by stimulation, which in turn is a cyclooxygenase (cyclooxygenase) Abbreviated as "COX" or two pathways of lipoxygenase to be metabolized into prostaglandins and leukotrienes, mediating various inflammatory responses (Thomas. R., Rev. Physiol. Biochem. Pharmacol ., 100, 1984).

최근, 피부 자극 및 염증의 생성을 줄일 수 있는 방법에 관한 연구가 활발히 진행되고 있으며, 지금까지의 연구 결과로는 신경세포에서 분비되는 물질 P (Substance P) 등의 신경 펩타이드나 자극에 의해 조직이나 혈장에서 활성화되는 브라디키닌과 같은 키닌(kinins) 등에 의해, 또는 COX 경로에 의해 형성된 다양한 사이토카인 및 프로스타글란딘 E2(prostaglandin E2, 이하 "PGE2"로 약칭) 등이 부종 형성과 혈관 확장에 관여하여 염증과 통증의 원인이 된다는 것이 알려져 있다. 이에 따라, 항염제로서는 물질 P를 비롯한 신경 펩타이드 길항제, 브라디키닌 길항제, COX 억제제 등이 제시되어 왔으나, 지금까지 알려진 항염제는 피부에 대한 안전성 면에서나, 제품에 포함시킬 때의 안정성 면에서 대부분 문제점을 안고 있어 그 사용이 제한되고 있다.In recent years, studies have been actively conducted on methods for reducing skin irritation and inflammation, and the results of the previous studies show that tissues may be produced by nerve peptides or stimuli such as substance P (Substance P) secreted from nerve cells. by a kinin (kinins) such as bradykinin which are activated in the plasma, or a variety of cytokines and prostaglandin E 2 edema formation and vascular expansion, etc. (referred to as prostaglandin E 2, hereinafter "PGE 2") formed by the COX route It is known to be involved and cause inflammation and pain. Accordingly, as anti-inflammatory agents, neuropeptide antagonists such as substance P, bradykinin antagonists, COX inhibitors, and the like have been proposed, but the anti-inflammatory agents known to date have most problems in terms of safety to the skin and stability when incorporated into the product. It is held and use is restricted.

이상과 같은 문제점을 고려하여, 본 발명에서는 항염 효과와 피부 안전성, 화장료 배합시 안정성 문제를 해결할 수 있는 항염물질을 탐색 연구하였으며, 기존의 항염물질에 비해 항염효과가 뛰어나면서 피부에 안전한 생약 추출물을 화장료에 적용하여 얻어지는 화장료 조성물을 제공하고자 하는 것을 목적으로 한다.In view of the above problems, the present invention has been conducted to search for anti-inflammatory substances that can solve the anti-inflammatory effect, skin safety, stability problems when formulating cosmetics, excellent anti-inflammatory effect compared to the existing anti-inflammatory substances, while extracting herbal extracts safe for skin It aims at providing the cosmetic composition obtained by applying to cosmetics.

상기 목적을 달성하기 위하여 본 발명에서는, 과루근, 대추 및 황백의 추출물을 유효성분으로 함유하는 항염효과를 갖는 화장료 조성물을 제공한다.In order to achieve the above object, the present invention provides a cosmetic composition having an anti-inflammatory effect containing an extract of fruit root, jujube and yellow white as an active ingredient.

여기에서, 상기 화장료 조성물은 과루근, 대추 및 황백의 추출물을 조성물 전체 중량에 대하여 0.001 내지 30.0 중량% 함유하는 것이 바람직하다.Here, the cosmetic composition preferably contains 0.001 to 30.0% by weight of the extract of fruit root, jujube and yellow white based on the total weight of the composition.

또한, 상기 추출물은 과루근, 대추 및 황백을 1:2:4의 중량비로 혼합하여 1,3-부틸렌글리콜, 정제수, 알콜, 에틸아세테이트, 아세톤, 또는 이들의 혼합 용매로 추출하여 얻을 수 있다.In addition, the extract may be obtained by mixing fruit root, jujube and yellow white in a weight ratio of 1: 2: 4 and extracting with 1,3-butylene glycol, purified water, alcohol, ethyl acetate, acetone, or a mixed solvent thereof. .

본 발명에서는 항염 효과와 피부 안전성, 화장료 배합시 안정성 문제를 해결하고 화장료에 쓸 수 있는 항염 물질을 탐색 연구하고자, 황백, 괴화, 작약, 삼백초, 음양곽, 당귀, 맥문동, 지모, 대추, 송이버섯, 쑥, 제비꽃, 오이, 죽순, 과루근, 백반, 당근 등의 천연식물 추출물들에 대해 피부 안전성, 항염 효과 등을 평가하였으며, 그 결과 피부에 가장 안전하면서도 효과적인 과루근, 대추 및 황백 추출물을 화장료에 적용할 경우 기존의 항염물질에 비해 항염효과가 뛰어나면서도 피부에 안전함을 발견하여 본 발명을 완성하게 되었다.In the present invention, the anti-inflammatory effect and skin safety, to solve the stability problems in the formulation of cosmetics and to study the anti-inflammatory substances that can be used in cosmetics, yellow white, chunks, peony, three hundred seconds, yin and yang, Dongguk, Mcmundong, jimo, jujube, pine mushroom Skin safety and anti-inflammatory effects of natural plant extracts such as mugwort, violet, cucumber, bamboo shoot, fruit root, alum, and carrot were evaluated, and as a result, the most safe and effective extract of fruit, jujube and yellow white extract was applied to cosmetics. When applied, it was found that the anti-inflammatory effect is superior to the existing anti-inflammatory substances and safe for the skin to complete the present invention.

본 발명에 따른 화장료 조성물에 유효성분으로서 포함되는 생약 추출물에 대해 구체적으로 살펴 보면, 먼저 과루근(瓜蔞根; Trichosanthes kirilowii Maxim)은 박과의 덩굴성 다년초로서 뿌리에 많은 녹말, 스티그마스테롤, β-시토스테롤, 사포닌, 염기성 단백질인 트리코산틴이 있다. 씨 기름의 지방산은 불포화 지방산 67%, 포화지방산 30%로 되어 있으며, 불포화 지방산의 대부분은 엘라에오스테아르산의 입체이성체로 생각되는 트리코산이다. 약리실험 결과 항암작용을 나타내며 적리균을 비롯한 병원성 미생물에 대한 억균작용을 나타낸다. 얼굴빛을 빛나게 하고 손과 발의 주름을 펴며, 피부점막에 자윤을 공급하고 각질제거를 원활히 도와주는 작용을 하는 것으로 알려져 있다.Looking specifically for the herbal extracts included as an active ingredient in the cosmetic composition according to the present invention, first, the fruit root (瓜 蔞 ris; Trichosanthes kirilowii Maxim) is a vine of perennial herbaceous perennial starch, stigmasterol, β There are cytosterols, saponins and trichosanthines, which are basic proteins. The fatty acids of the seed oil are 67% unsaturated fatty acids and 30% saturated fatty acids, and most of the unsaturated fatty acids are trichoic acid which is considered to be a stereoisomer of ellaostearic acid. Pharmacological experiments show anticancer activity and bacteriostatic action against pathogenic microorganisms including erythrocytes. It is known to shine the face light, to spread the wrinkles of hands and feet, to supply skin mucous membranes and to help exfoliate smoothly.

또한, 대추(jujube; Zizyphus jujuba Miller)는 갈매나무목 갈매나무과의 낙엽교목으로, 과실에는 단백질, 당류, 유기산, 점액질, 비타민 A, B2, C와 칼륨, 칼슘, 인 등의 무기질과 비타민 B, 당분 등 성분을 많이 함유하고 있다. 자양강장 이뇨제(滋養强壯 利尿劑)로서 진정 및 수렴 작용과 함께 보중익기(補中益氣)하며, 얼굴색을 좋게 하는 작용을 하는 것으로 알려져 있다. 또한 항산화 및 노화 예방 효과가 있으며, 피부 각질 제거 및 항알러지 효과도 있다고 되어 있다.In addition, jujube ( Zizyphus jujuba Miller) is a deciduous tree of the sea buckthorn, and the fruit contains proteins, sugars, organic acids, mucus, vitamins A, B 2 , C, potassium, calcium, phosphorus and other minerals such as vitamin B, It contains many ingredients such as sugar. As a nourishing tonic diuretic, it is known to have a sedative and astringent effect, with a beneficial effect, and to improve the color of the face. It also has antioxidant and anti-aging effects, exfoliating skin and anti-allergic effects.

황백(黃柏; Phellodendri Cortex)은 황백나무(황경피나무; Phellodendron amurense Ruprcht(운향과)) 또는 그 밖의 동속식물의 주피를 벗겨낸 줄기껍질로서, 자연생의 줄기 일부의 껍질을 벗기거나 또는 벌목에 의해 껍질을 완전히 벗겨 그대로 음건시킨 것이다. 황백의 성분으로는 껍질 성분으로서 알칼로이드계 성분, 고미성 물질, 스테로이드계 성분 등, 과실 성분으로서 정유, 미르센(myrcene), 지방유 등, 잎 성분으로서 펠라빈, 펠라틴, 펠로덴드로시드, 아무레신 등이 있다. 황백의 주성분인 베르베린(berberine)은 항세균 작용과 살균 작용, 항균 작용과 더불어 종양세포에도 작용하여 그 생활기능을 저지시킨다는 보고가 있다. 또한 항산화와 노화예방 효과도 있으며 피부 면역력을 강화시키는 효능도 있다고 한다.Phellodendri Cortex is a stem bark peeled from the main bark of a rhododendron ( Phellodendron amurense Ruprcht) or other species of the same species. Completely peeled off as it was in the shade. As a component of the yellowish white skin, alkaloid-based ingredients, high-grade substances, steroid-based ingredients, etc., fruit ingredients such as essential oils, myrcene (myrcene) and fatty oils; Etc. Berberine, the main component of yellow and white, has been reported to act on tumor cells in addition to antibacterial, bactericidal and antimicrobial effects and to inhibit its life function. It also has anti-oxidant and anti-aging effects, and is said to boost skin immunity.

본 발명에 따른 화장료 조성물은 다음과 같이 제조된다.The cosmetic composition according to the present invention is prepared as follows.

먼저 본 발명에 사용된 생약을 추출하는데, 과루근, 대추 및 황백을 각각 1:2:4의 중량비로 혼합하여 1,3-부틸렌글리콜, 정제수, 탄소수 1 내지 4의 저급알콜, 에틸아세테이트, 아세톤, 또는 이들의 혼합 용매로 추출할 수 있으며, 추출 후에는 필터를 이용하여 여과한다. 생약의 혼합 비율이 위의 비율을 벗어나는 경우에는 화장료에 적용시 저온에서 침전물이 생기는 등 안정성에 문제가 있고, 화장료의 색상 조절이 좋지 않아 바람직하지 않다.First, the herbal medicine used in the present invention is extracted, and 1,3-butylene glycol, purified water, lower alcohol having 1 to 4 carbon atoms, ethyl acetate It can be extracted with acetone or a mixed solvent thereof, and after extraction, it is filtered using a filter. If the mixing ratio of the herbal medicine is out of the above ratio, there is a problem in stability, such as a precipitate occurs at low temperatures when applied to the cosmetic, it is not preferable because the color control of the cosmetic is not good.

이와 같이 제조된 생약 추출물은 화장료 조성물 총 중량에 대하여 0.001 내지 30%(w/w), 바람직하게는 0.01 내지 20%(w/w)의 비율로 포함된다. 생약 추출물 함량이 0.001% 보다 적게 포함되는 화장료 조성물에서는 실질적인 항염효과를 기대하기 어렵고, 반면 생약 추출물 농도가 30%를 초과하는 경우에는 생약의 향취를 마스킹(masking)하기 어렵고, 오히려 피부에 좋지 않은 영향을 줄 뿐 아니라, 원가 상승에 따른 효능 대비 경제적 가치도 떨어지기 때문에 바람직하지 않다.The herbal extract thus prepared is included in a ratio of 0.001 to 30% (w / w), preferably 0.01 to 20% (w / w) based on the total weight of the cosmetic composition. It is difficult to expect a substantial anti-inflammatory effect in cosmetic compositions containing less than 0.001% herbal extract content, whereas when the herbal extract concentration exceeds 30%, it is difficult to mask the fragrance of the herbal medicine, but rather adversely affects the skin. In addition, it is not preferable because it lowers the economic value compared to the efficacy of the cost increase.

이하, 실시예 및 시험예를 통하여 본 발명을 더욱 구체적으로 설명한다. 단, 이들 실시예 등은 본 발명의 예시일 뿐, 본 발명의 범위가 이들만으로 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to Examples and Test Examples. However, these Examples etc. are only illustrations of this invention, The scope of the present invention is not limited only to these.

제조예 : 생약 추출물의 제조Preparation Example: Preparation of Herbal Extract

과루근, 대추 및 황백 생약을 물로 세척한 후 잘게 세절하여 1:2:4의 중량비로 혼합하였다. 한약재 복합물 1 ㎏ 당 부틸렌글리콜 5 ㎏을 첨가하여 실온에서 5 내지 7 일간 추출한 다음, 추출물을 0.5 ㎛ 크기의 필터로 1 차 여과하고 이온교환수지를 통과시켰다. 이후 다시 3 ㎛ 필터로 여과하고, 이를 통과한 추출물을 또 다시 0.2 ㎛ 필터로 여과하여 최종 생약 추출물을 얻었다(회수율 58.3%).Fruits, jujube and yellow white herb were washed with water and finely chopped and mixed in a weight ratio of 1: 2: 4. 5 kg of butylene glycol was added per 1 kg of the herbal medicine complex, followed by extraction at room temperature for 5 to 7 days, and then the extract was first filtered through a 0.5 μm filter and passed through an ion exchange resin. Thereafter, the resultant was filtered again using a 3 μm filter, and the extract passed through the filter was further filtered through a 0.2 μm filter to obtain a final herbal extract (58.3% recovery).

효과 시험예 1: PGEEffect Test Example 1: PGE 22 생성 억제 효과 시험 Production inhibitory effect test

생약 추출물의 COX-2 활성에 대한 영향을 알아보기 위하여 하기 실험을 실시하였다(참고문헌: Jeffrey, K. H., Anglea, S. W., Zoe, S., and Rhia C. M. Intracellular Measurement of Prostaglandin E2: Effect of Anti-inflammatory Drugs on Cyclooxygenase Activity and Prostanoid Expression, Analytical Biochemistry, 1999, 271, 18-28).The following experiments were conducted to investigate the effect of herbal extracts on COX-2 activity (Ref .: Jeffrey, KH, Anglea, SW, Zoe, S., and Rhia CM Intracellular Measurement of Prostaglandin E2: Effect of Anti-inflammatory Drugs on Cyclooxygenase Activity and Prostanoid Expression, Analytical Biochemistry , 1999, 271, 18-28).

사람의 표피 조직에서 분리한 섬유아세포를 수 차례 계대 배양한 후, 96-웰 플레이트에 1×105 개씩 넣고 24 시간 배양하였다. FBS가 포함되지 않은 배지로 교체하여 2 시간 배양하여, 평가하고자 하는 원료인 생약 추출물을 하기 표 1에 나타낸 농도로 처리하고, 이때 인도메타신(indomethacin)도 비교군으로 함께 처리하여 1 시간 동안 배양한 후, 자극원으로 칼슘 이오노포어 A23187(Calcium ionophore A23187)과 아라키돈산을 50 mM 농도로 처리하여 37 ℃에서 5 분간 배양하였다. 도데실트리메틸암모늄 브로마이드(dodecyltrimethylammonium bromide)를 최종 농도 0.25%로 10 분간 처리하여 세포를 용혈시키고, 상층액을 적당량 취하여 PGE2의 양을 효소면역분석법(Enzyme-Linked Immunosorbent Assay, ELISA)을 이용하여 정량함으로써 생약추출물의 프로스타글란딘 억제 효과를 판단하였다. 그 결과를 다음 표 1에 나타낸다.After several passages of fibroblasts isolated from human epidermal tissue, 1 × 10 5 cells were placed in 96-well plates and incubated for 24 hours. Incubated for 2 hours by replacing with a medium that does not contain FBS, the herbal extract as a raw material to be evaluated is treated at the concentrations shown in Table 1, and indomethacin (indomethacin) is also treated with a comparative group and cultured for 1 hour. After that, calcium ionophore A23187 (Calcium ionophore A23187) and arachidonic acid were treated at 50 mM to incubate at 37 ° C. for 5 minutes. Dodecyltrimethylammonium bromide was treated for 10 minutes with a final concentration of 0.25% for 10 minutes to hemolyse the cells, and the appropriate amount of supernatant was taken to quantify the amount of PGE 2 using Enzyme-Linked Immunosorbent Assay (ELISA). By judging the prostaglandin inhibitory effect of the herbal extracts. The results are shown in Table 1 below.

시 료sample 농도 (%)Concentration (%) PGE2(pg/웰)PGE 2 (pg / well) PGE2증가PGE 2 increase 억제율 (%)Inhibition Rate (%) 음성대조군Negative Control 2121 양성대조군(+아라키돈산)Positive control group (+ arachidonic acid) 240240 219219 양성대조군(+인도메타신)Positive control group (+ indomethacin) 3535 1414 93.693.6 생약 추출물Herbal extract 0.010.01 165165 144144 34.234.2 0.10.1 122122 101101 53.953.9 0.50.5 165165 144144 34.234.2

표 1에서 보듯이, 생약 추출물은 최고 53.9%까지의 높은 프로스타글란딘 (PGE2) 억제율을 나타내어, COX-2 효소의 유도 작용 또는 활성 억제를 통한 항염 효능이 매우 우수함을 알 수 있다.As shown in Table 1, the herbal extract shows a high prostaglandin (PGE 2 ) inhibition rate of up to 53.9%, it can be seen that the anti-inflammatory effect through the induction or inhibition of the COX-2 enzyme is very excellent.

효과 시험예 2: 항염 효과 시험Effect Test Example 2: Anti-inflammatory Effect Test

생약 추출물의 항염 효과를 알아보기 위하여, 아라키돈산(arachidonic acid)을 이용한 평가법(A. Crummey, G. P. Harper, E. A. Boyle and F. R. Mangan. Inhibition of arachidonic acid-induced ear edema as a model for assessing topical anti-inflammatory compound. Agents and Actions, 1987, 20: 69-76)을 이용하였다.To investigate the anti-inflammatory effect of herbal extracts, A. Crummey, GP Harper, EA Boyle and FR Mangan.Inhibition of arachidonic acid-induced ear edema as a model for assessing topical anti-inflammatory compound.Agents and Actions, 1987, 20: 69-76.

마우스(hairless mouse) 35 마리를 각 7 마리씩 나누고, 시료 적용 전 양쪽 귀를 에탄올로 깨끗이 세척한 후 마이크로미터를 이용하여 측정하고, 생약 추출물 0.5% 또는 1.0%를 처리하는 시료군과 인도메타신(indomethacin) 1.0%를 처리하는 비교군, 그리고 아라키돈산만을 처리하는 대조군으로 나누어 실험을 실시하여 마우스의 귀 두께 평균치를 측정하였다. 생약 추출물을 처리하는 시료군과 인도메타신을 처리하는 비교군은 시료 20 ㎕를, 대조군에는 에탄올 20 ㎕를 1 일 1 회씩 4 일간 지속적으로 도포하였다. 마지막으로 도포하고 1 시간 경과 후, 좌측에는 에탄올을, 우측 귀에는 아라키돈산을 2 ㎎/ear씩 도포하고, 도포 1 시간 후 귀의 부종 (edema) 정도를 마이크로미터를 이용하여 양쪽 귀에 대하여 3 회씩 반복 측정하였다. 처리군의 좌측 귀는 시료 자체에 의한 염증 유발 정도를 알아보기 위한 대조군으로 이용하였다. 항염 효과는 아라키돈산만을 처리한 대조군을 기준으로 부종 억제 정도를 판정하였으며, 그 결과를 표 2에 나타낸다.Each of 35 hairless mice was divided into 7 animals, and both ears were thoroughly washed with ethanol prior to sample application, and measured using a micrometer. A sample group and indomethacin (0.5% or 1.0% herbal extract) were treated. Indomethacin) was divided into a comparison group treated with 1.0% and a control group treated with only arachidonic acid to measure the average ear thickness of the mouse. The sample group treated with the herbal extracts and the comparative group treated with indomethacin were continuously applied with 20 μl of the sample and 20 μl of ethanol to the control group once daily for 4 days. One hour after the last application, ethanol was applied on the left side and arachidonic acid was applied on the right ear by 2 mg / ear. After 1 hour of application, the edema of the ear was repeated three times on both ears using a micrometer. Measured. The left ear of the treated group was used as a control to determine the degree of inflammation caused by the sample itself. The anti-inflammatory effect was determined in the degree of inhibition of edema based on the control group treated with arachidonic acid only, the results are shown in Table 2.

시 료sample 농도(%)density(%) 귀두께(㎛)Ear thickness (㎛) 억제율(%)% Inhibition 시료 처리 전Before sample processing 시료 처리 후After sample processing 시료군Sample group 생약 추출물Herbal extract 1.01.0 352352 550550 17.517.5 비교군Comparison 인도메타신Indomethacin 1.01.0 357357 497497 41.741.7 대조군Control 아라키돈산Arachidonic acid 2 ㎎/ear2 mg / ear 333333 573573

억제율(%)=(A-B)/A×100 Inhibition rate (%) = (AB) / A * 100

A: 대조군 귀의 평균 두께 변화A: average thickness change of control ear

(아라키돈산 처리 귀의 두께-아라키돈산 비처리 귀의 두께)(Thickness of arachidonic acid-treated ear-thickness of arachidonic acid untreated ear)

B: 시료 도포군 귀의 평균 두께 변화B: Average thickness change of sample application group ears

(시료 처리 귀의 두께-시료 비처리 귀의 두께)(Thickness of the sample processing ear-thickness of the sample non-processing ear)

표 2에서 보듯이, 본 발명의 생약 추출물 1.0% 시료는 17.5%의 염증 억제율을 나타내었다. 이러한 수치는 의약품 성분으로서 항염 효과가 매우 우수한 물질인 인도메타신(indomethacin) 대비 약 42% 정도의 항염 효과로, 항염 물질로 사용되고 있는 마치현 추출물의 염증 억제율 20.5% 보다는 다소 낮으나 사용하기에는 충분한 정도로 사료된다. 또한, 부종 증가율로 유의차 검증시, 생약 추출물은 아라키돈산과 99%의 유의차를 갖는 효과를 나타내었다.As shown in Table 2, the 1.0% sample of the herbal extract of the present invention showed an inhibition rate of 17.5%. This figure is about 42% of the anti-inflammatory effect compared to indomethacin, which is an excellent anti-inflammatory effect as a pharmaceutical ingredient. . In addition, when the significant difference was verified by the increase rate of edema, the herbal extract showed an effect having a significant difference of 99% with arachidonic acid.

효과 시험예 3: 세포독성 시험 Effect Test Example 3 3: Cytotoxicity Test

화장품에 사용되는 원료로서 1차 안전성을 검증하고자, 본 발명의 생약 추출물에 대하여 V79-4세포(차이니스 햄스터, 폐조직 섬유 아세포의 연속 세포주)을 배양하여 MTT 시험을 하는 방법(참고문헌: Mossman T. (1983). Rapid colorimetric assay for cellular growth & survival: application to proliferation & cytotoxicity assays. Journal of Immunological Methods, 65, 55-63)을 수행하여 세포독성을 시험하였으며, 그 결과를 표 3에 나타낸다.In order to verify primary safety as a raw material used in cosmetics, a method of MTT test by culturing V79-4 cells (Chinese hamster, continuous cell line of lung tissue fibroblasts) to the herbal extract of the present invention (Reference: Mossman T. (1983) Rapid colorimetric assay for cellular growth & survival: application to proliferation & cytotoxicity assays. Journal of Immunological Methods , 65, 55-63) were performed to test the cytotoxicity, the results are shown in Table 3.

시료sample aIC50(%,W/V) a IC 50 (%, W / V) 소디움라우릴설페이트(SLS)Sodium Lauryl Sulfate (SLS) 0.0050.005 스쿠알란Squalane 0.050.05 생약 추출물Herbal extract 5.05.0

aIC50: Inhibitory Concentration 50, 50%의 세포를 사멸시키는 농도 a IC 50 : Inhibitory Concentration 50, 50% cell killing concentration

표 3에서 보는 바와 같이, 본 발명에 따른 생약 추출물의 IC50 값은 5.0으로 소디움라우릴설페이트에 비하여 1000 배 이상 세포독성이 낮을 뿐 아니라, 안전성이 우수한 유용성 원료인 스쿠알란보다 100 배 낮은 세포독성을 나타내어, 그 안전성이 우수함을 알 수 있다.As shown in Table 3, the IC 50 value of the herbal extract according to the present invention is 5.0, which is not only 1000 times lower in cytotoxicity than sodium lauryl sulfate, but 100 times lower in cytotoxicity than squalane, which is an excellent safety ingredient. It is shown that the safety is excellent.

효과 시험예 4: 알러지 평가(LLNA)Effect test example # 4: allergy evaluation (LLNA)

본 발명에 따른 생약 추출물의 알러지 유발 여부를 확인하기 위한 실험으로서, 운반 매개물로 아세톤:올리브 오일(4:1)을 사용하는 실험법을 택하였다(참고문헌: Kimber I(1990): Identification of contact allergens using the murine local lymph node assay, J. Appl. Toxicol., 10(3), 173-180). 즉, 생약 추출물을 20%, 40% 및 60% 용액으로 제조하여 마우스(Balb/c)의 양쪽 귀에 50 ㎕씩 3 일간 발라준 후, 쥐로부터 이개임파절(auricular lymph node)을 분리하였다. 임파절을 분쇄하여 단일세포 상태로 만들고 방사성 동위원소(3H-티미딘)를 첨가하여 24 시간 배양한 다음, 세포의 증폭도[cpm]를 측정하였다. 그 결과를 표 4에 나타낸다.As an experiment to determine whether the herbal extracts according to the present invention are allergenic, an experiment using acetone: olive oil (4: 1) as a carrier medium was selected (Kimber I (1990): Identification of contact allergens). using the murine local lymph node assay, J. Appl. Toxicol., 10 (3), 173-180). That is, herbal extracts were prepared in 20%, 40%, and 60% solutions, 50 μl was applied to both ears of the mouse (Balb / c) for 3 days, and auricular lymph nodes were isolated from the rats. Lymph nodes were pulverized to a single cell state and cultured for 24 hours with the addition of radioisotope ( 3 H-thymidine), and then the amplification degree [cpm] of the cells was measured. The results are shown in Table 4.

시료sample 림프절?세포(107?세포/㎖)Lymph node cells (10 7 cells / ml) cpm(평균)cpm (average) 증폭도Amplification 아세톤:올리브오일(4:1)Acetone: Olive Oil (4: 1) 1.891.89 14401440 운반매개물Transportation 생약 추출물?20%Herbal Medicine Extract? 20% 2.012.01 16661666 1.21.2 생약 추출물?40%Herbal Medicine Extract? 40% 1.711.71 12531253 0.90.9 생약 추출물?60%Herbal Medicine Extract? 60% 1.881.88 12231223 0.80.8

표 4에서 보는 바와 같이, 본 발명에 따른 생약 추출물은 최고 증폭도(S.I.)가 3 이하로서 알러지 유발 가능성이 거의 없는 것으로 나타났다.As shown in Table 4, the herbal extracts according to the present invention were shown to have the highest amplification degree (S.I.) of 3 or less, and have almost no allergic potential.

효과 시험예 5: 인체에 대한 1차 자극성 시험(폐쇄 첩포)Effect Test Example 5: Primary irritation test on human body (closed patch)

생약 추출물 1.0%, 소디움라우릴설페이트 1.0% 및 에탄올 10%를 함유한 시료와 소디움라우릴설페이트 1.0% 용액, 에탄올 10% 용액의 안전성을 알아보기 위하여, 하기와 같이 인체 첩포 시험(human patch test)을 통해 인체에 대한 1 차 자극시험을 행하였다. 건강한 성인 남녀 50명을 대상으로 CTFA 가이드라인(The Cosmetic, Toiletry and Fragrance Association. Inc. Washington, D.C., 20036, 1991)에 따라 실시하였다. 즉, 핀 챔버(Finn Chamber)에 시료 및 용액 20 ㎕를 적하한 후, 이것을 시험 부위인 인체의 등에 얹어 테이프로 고정시켰다. 이어서 24 시간 동안 첩포한 후 첩포를 제거하고, 다시 4 시간 경과한 다음 시험 부위의 피부 반응을 다음 기준에 따라 판정하였다. 그 결과를 표 5에 나타낸다.In order to determine the safety of the sample containing 1.0% herbal extract, 1.0% sodium lauryl sulfate and 10% ethanol, and 1.0% solution of sodium lauryl sulfate and 10% ethanol solution, the human patch test was performed as follows. Through the first stimulation test on the human body was done. Fifty healthy men and women were tested according to CTFA guidelines (The Cosmetic, Toiletry and Fragrance Association. Inc. Washington, D.C., 20036, 1991). That is, 20 µl of the sample and the solution were dropped into a Fin chamber, and it was placed on the back of the human body as a test site and fixed with tape. Subsequently, after patching for 24 hours, the patch was removed, after another 4 hours, the skin reaction at the test site was determined according to the following criteria. The results are shown in Table 5.

<판정 기준><Judge criteria>

-; 홍반이나 특이한 현상 없음-; No erythema or unusual symptoms

±; 주위보다 약간 붉어짐±; Slightly redder than the surroundings

+; 주위보다 현저히 붉어짐+; Significantly redder than the surroundings

++; 주위보다 심하게 붉어지고 부풀어 오름+ +; Severe redness and swelling than around

자극도=[{(±)수×1}+{(+)수×2}+{(++)수×3}]/피시험자 수Stimulus level = [{(±) number × 1} + {(+) number × 2} + {(++) number × 3}] / Number of subjects

시료sample 피검자수The number of the subjects 판정결과Judgment result 자극도Stimulus ++++ ++ ±± -- 생약 추출물(1.0%), 소디움라우릴설페이트(1%) 및 에탄올(10%)Herbal Extract (1.0%), Sodium Lauryl Sulfate (1%) and Ethanol (10%) 5050 -- -- 55 4545 0.100.10 소디움라우릴설페이트(1%)Sodium Lauryl Sulfate (1%) 5050 22 88 1212 2828 0.680.68 에탄올(10%)Ethanol (10%) 5050 -- -- 1010 4040 0.200.20

표 5에서 보듯이, 본 발명에 따른 생약 추출물 1.0%는 소디움라우릴설페이트 1.0%와 에탄올 10%의 자극을 크게 완화시켜주는 것을 알 수 있다. 이와 같은 결과는 전술한 항염 효과 실험에서 나타난 바와 같이 본 발명에 따른 생약 추출물의 뛰어난 염증 완화 효과에 기인된 것으로 사료된다. As shown in Table 5, the herbal extract 1.0% according to the present invention can be seen to greatly alleviate the stimulation of sodium lauryl sulfate 1.0% and ethanol 10%. This result is believed to be due to the excellent anti-inflammatory effect of the herbal extract according to the present invention as shown in the anti-inflammatory effect experiment described above.

이상에서 살펴본 효과 시험예들로부터 본 발명에 따른 생약 추출물은 항염 효과가 뛰어나고 피부에 안전한 성분임을 알 수 있다.Herbal extracts according to the present invention from the above-described effect test examples can be seen that the anti-inflammatory effect is excellent and safe ingredients for the skin.

다음은, 항염 및 항자극 효과가 우수하며 피부에 안전한 본 발명에 따른 생약 추출물을 이용하여 화장료 조성물을 제조한 예를 보여준다.The following shows an example of preparing a cosmetic composition using the herbal extract according to the present invention, which has excellent anti-inflammatory and anti-irritant effects and is safe for skin.

실시예 1: 화장수 제조Example 1: Make-up

다음 표 6의 처방을 가지고 통상의 방법에 따라 화장수를 제조하였다.To prepare a lotion according to a conventional method with the prescription of the following Table 6.

원료명Raw material name 중량%(w/w)Weight% (w / w) 글리세린디프로필렌글리콜히아루론산폴리옥시에틸렌 경화피마자유폴리에틸렌올레일에틸에탄올방부제향료색소생약 추출물정제수Glycerin dipropylene glycol hyaluronic acid polyoxyethylene cured castor oil polyethylene oleyl ethyl ethanol preservative flavoring pigment herbal extract extract water 5.03.00.50.10.15.00.15적량적량0.001100이 되도록 첨가5.03.00.50.10.15.00.15 Add to make appropriate quantity 0.001100

실시예 2: 에센스 제조Example 2: Essence Preparation

다음 표 7의 처방을 가지고 통상의 방법에 따라 에센스를 제조하였다.The essence was prepared according to a conventional method with the prescription of the following Table 7.

원료명Raw material name 중량%(w/w)Weight% (w / w) 세토스테아릴알콜자기유화형 모노스테아린산밀납스쿠알란이소세틸옥타노에이트디메틸실록산모노스테아린산소르비탄모노스테아린산폴리에틸렌글리콜글리세린프로필렌글리콜카르복시폴리머트리에탄올아민방부제향료색소생약 추출물정제수Cetostearyl alcohol Self-emulsifying monostearic acid beeswax squalane isocetyl octanoate dimethyl siloxane stearic acid sorbitan monostearic acid polyethylene glycol glycerin propylene glycol carboxypolymer triethanolamine preservative flavoring pigment extract extract 1.01.00.55.03.00.30.58.04.00.20.220.25적량적량적량0.01100이 되도록 첨가1.01.00.55.03.00.30.58.04.00.20.220.25 Appropriate quantity added to make 0.011100

실시예 3: 로션 제조Example 3: Lotion Preparation

다음 표 8의 처방을 가지고 통상의 방법에 따라 로션을 제조하였다.The lotion was prepared according to a conventional method with the prescription of the following Table 8.

원료명Raw material name 중량%(w/w)Weight% (w / w) 세토스테아릴알콜자기유화형 모노스테아린산밀납스테아린산유동파라핀스쿠알란마카데미아 오일이소세틸옥타노에이트디메틸실록산모노스테아린산소르비탄모노스테아린산폴리에틸렌글리콜글리세린프로필렌글리콜베타인카르복시폴리머트리에탄올아민방부제향료색소생약 추출물정제수Cetostearyl Alcohol Self-emulsifying Monostearic acid Beeswax Stearic Acid Liquid Paraffin Squalane Alkama Demia Oil Isocetyl Octanoate Dimethylsiloxane Monostearic Acid 0.81.00.50.57.05.03.02.00.30.51.24.04.04.00.120.150.25적량적량5.0100이 되도록 첨가0.81.00.50.57.05.03.02.00.30.51.24.04.04.00.120.150.25 Appropriate amount added to make 5.0100

실시예 4: 크림 제조Example 4: Cream Preparation

다음 표 9의 처방을 가지고 통상의 방법에 따라 크림을 제조하였다.To prepare a cream according to the conventional method with the prescription of Table 9.

원료명Raw material name 중량%(w/w)Weight% (w / w) 세토스테아릴알콜자기유화형 모노스테아린산친유형 모노스테아린산밀납유동파라핀스쿠알란이소세틸옥타노에이트정제 호호바유디메틸실록산모노스테아린산소르비탄모노스테아린산폴리에틸렌글리콜글리세린프로필렌글리콜베타인잔탄검트리에탄올아민방부제향료색소생약 추출물정제수Cetostearyl alcohol Self-emulsifying monostearic acid lipophilic monostearic acid beeswax liquid paraffin squalane isocetyl octanoate tablets jojoba oil dimethyl siloxane monostearic acid sorbitan monostearic acid polyethylene glycol glycerol propylene glycol betaine xanthan gum triethanolamine antiseptic flavoring extract 3.01.51.50.58.07.04.04.00.31.01.26.04.04.00.060.100.25적량적량10.0100이 되도록 첨가3.01.51.50.58.07.04.04.00.31.01.26.04.04.00.060.100.25 Appropriate quantity added to 10.0100

실시예 5: 젤의 제조Example 5: Preparation of Gel

다음 표 10의 처방을 가지고 통상의 방법에 따라 젤을 제조하였다.Next, the gel was prepared according to the conventional method with the prescription of Table 10.

원료명Raw material name 중량%(w/w)Weight% (w / w) 글리세린프로필렌글리콜에탄올폴리옥시에틸렌경화피마자유카르복시폴리머트리에탄올아민방부제향료색소생약 추출물정제수Glycerin Propylene Glycol Ethanol Polyoxyethylene Cured Castor Oil Carboxy Polymer Triethanolamine Preservatives Pigment Herbal Extract Extract 4.04.0100.10.300.30적량적량적량20.0100이 되도록 첨가4.04.0100.10.300.30 Appropriate quantity added to be 20.0100

실시예 6: 연고의 제조Example 6: Preparation of Ointment

다음 표 11의 처방을 가지고 통상의 방법에 따라 연고를 제조하였다.The ointment was prepared according to a conventional method with the prescription of Table 11.

원료명Raw material name 중량%(w/w)Weight% (w / w) 세토스테아릴알콜자기유화형 모노스테아린산스테아린산밀납스쿠알란모노스테아린산글리세린모노스테아린산소르비탄폴리솔베이트 80글리세린프로필렌글리콜향료색소생약추출물바세린Cetostearyl alcohol self-emulsifying monostearate stearic acid beeswax squalane monostearic acid glycerin monostearic acid sorbitan polysorbate 80 glycerin propylene glycol flavoring pigment herbal extract petroleum jelly 2.02.01.04.07.03.01.03,05.04.0적량적량30.0100이 되도록 첨가2.02.01.04.07.03.01.03,05.04.0 Appropriate quantity added to be 30.0100

이상에서 설명한 바와 같이, 본 발명에 따른 생약 추출물은 세포독성, 알러지 유발 가능성 등의 면에서 피부에 안전할 뿐 아니라, COX-2 경로의 염증 유발 에이코사노이드(eicosanoid)인 PGE2의 생성을 억제하는 등 항염 효과가 우수하여, 이 생약 추출물을 화장품 조성물에 유효성분으로 함유시키는 것에 의하여 우수한 항염효과를 갖는 화장료 조성물을 얻을 수 있다.As described above, the herbal extract according to the present invention is not only safe for the skin in terms of cytotoxicity and allergic potential, but also inhibits the production of PGE 2 , an inflammation-inducing eicosanoid of the COX-2 pathway. The anti-inflammatory effect is excellent, and the cosmetic composition which has the excellent anti-inflammatory effect can be obtained by containing this herbal extract as an active ingredient in a cosmetic composition.

Claims (3)

과루근, 대추 및 황백의 추출물을 유효성분으로 함유하는, 항염 효과를 갖는 화장료 조성물.Cosmetic composition having an anti-inflammatory effect, containing extracts of fruit root, jujube and yellow white as active ingredients. 제 1 항에 있어서, 과루근, 대추 및 황백의 추출물을 조성물 전체 중량에 대하여 0.001 내지 30.0 중량% 함유하는 화장료 조성물.The cosmetic composition according to claim 1, which contains 0.001 to 30.0% by weight of extracts of fruit root, jujube and yellow white based on the total weight of the composition. 제 1 항 또는 제 2 항에 있어서, 상기 추출물은 과루근, 대추 및 황백을 1:2:4의 중량비로 혼합하여 1,3-부틸렌글리콜, 정제수, 알콜, 에틸아세테이트, 아세톤, 또는 이들의 혼합 용매로 추출한 것인 화장료 조성물.The method according to claim 1 or 2, wherein the extract is mixed with fruit root, jujube and yellow white in a weight ratio of 1: 2: 4 1,3-butylene glycol, purified water, alcohol, ethyl acetate, acetone, or their Cosmetic composition extracted with a mixed solvent.
KR1020030061716A 2003-09-04 2003-09-04 Cosmetics containing natural herb extract having anti-inflammatory effect KR20050024831A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020030061716A KR20050024831A (en) 2003-09-04 2003-09-04 Cosmetics containing natural herb extract having anti-inflammatory effect

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020030061716A KR20050024831A (en) 2003-09-04 2003-09-04 Cosmetics containing natural herb extract having anti-inflammatory effect

Publications (1)

Publication Number Publication Date
KR20050024831A true KR20050024831A (en) 2005-03-11

Family

ID=37231901

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020030061716A KR20050024831A (en) 2003-09-04 2003-09-04 Cosmetics containing natural herb extract having anti-inflammatory effect

Country Status (1)

Country Link
KR (1) KR20050024831A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100720670B1 (en) * 2006-02-22 2007-05-21 경희대학교 산학협력단 The composition comprising extracts of phellodendri cortex and coptis chinensis for treatment of type iv allergy and an inflammation
KR100879032B1 (en) * 2007-05-09 2009-01-15 (주)한스킨 Natural antibacterial extracts and cosmetic composition comprising the extracts
KR101315160B1 (en) * 2006-07-04 2013-10-08 엘브이엠에이취 러쉐르쉐 Cosmetic composition containing an extract of limnocitrus littoralis

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100720670B1 (en) * 2006-02-22 2007-05-21 경희대학교 산학협력단 The composition comprising extracts of phellodendri cortex and coptis chinensis for treatment of type iv allergy and an inflammation
KR101315160B1 (en) * 2006-07-04 2013-10-08 엘브이엠에이취 러쉐르쉐 Cosmetic composition containing an extract of limnocitrus littoralis
KR100879032B1 (en) * 2007-05-09 2009-01-15 (주)한스킨 Natural antibacterial extracts and cosmetic composition comprising the extracts

Similar Documents

Publication Publication Date Title
Pundir et al. Ethnomedicinal uses, phytochemistry and dermatological effects of Hippophae rhamnoides L.: A review
Lall et al. Are plants used for skin care in South Africa fully explored?
Kole et al. Cosmetic potential of herbal extracts
KR20070079596A (en) Composition of funtional cosmestic for subsidiary skin trouble treatment
CN105726391B (en) A kind of dendrobium candidum shower cream
KR20120000880A (en) Cosmetic composition comprising naturalplant extract for alleviating atopic dermatitis
KR20110082292A (en) Antipuritis and antiance effects of dendropanax morbifera lev. extract
JP2020514279A (en) Composition comprising an extract of a Hedychium coronarium species plant for use in a method of therapeutically treating the human body
KR20190124947A (en) Cosmetic composition and skin extrnal composition comprising turmeric extract and camellia oil
KR20180101124A (en) Cosmetic composition for improving skin inflammation comprising horse oil and sprout extracts
Calabrese et al. Hormesis: Wound healing and keratinocytes
KR101397160B1 (en) Cosmetic compositon for skin-irritation alleviation with Inula britannica var. chinensis, Cynanchi Radix and Lysimachia foenum-graecum Hance
KR102214985B1 (en) Compositions for improving skin conditions comprising plant extracts or fractions thereof
KR20210018388A (en) Compositions for improving skin conditions comprising plant extracts or fractions thereof
KR20100089409A (en) Cosmetic composition for acne improvement
KR20080001031A (en) A cosmetic composition for wrinkle improvement containing a extract of prunella vulgaris
KR101459742B1 (en) Cosmetic composition for improving acne containing extracts of natural substance
CN110787119A (en) Antibacterial skin-care traditional Chinese medicine composition and preparation method and application thereof
KR101252560B1 (en) Cosmetic composition containing extracts of Impatiens balsamina L. for controlling anti-acne or anti-comedone
CN114502139B (en) Moringa oleifera seed extract enriched in 2, 5-diformylfuran, method for obtaining same and use thereof in cosmetic compositions
KR20110085543A (en) Cosmetic composition for alleviating skin inflammation
KR20050024831A (en) Cosmetics containing natural herb extract having anti-inflammatory effect
KR20160003920A (en) Cosmetic composition for anti-inflammation or improving skin trouble containing herb extracts
KR20060099225A (en) Composition containing hovenia dulcis fruit extract having anti-inflammatory effect and use thereof
KR20020044267A (en) Cosmetic composition for skin whitening comprising an extract from rubus coreanus miq

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application